FDA Clears Labeling Update for Exelixis's COMETRIQ, No New Use Added
The FDA approved a labeling supplement for Exelixis's COMETRIQ (cabozantinib) on Nov. 19, 2026, refreshing the prescribing and patient package inserts. No new indication, safety or efficacy change came with it — this one is housekeeping for a drug already on the market.
- Original source: quantisnow.com.
- The source published it on Nov 20, 2026 at 10:48 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Exelixis picked up an FDA approval for its cancer drug COMETRIQ on Nov. 19, 2026. The action covers supplement SUPPL-15 to New Drug Application 203756, the filing tied to cabozantinib. It touches only the patient package insert and the package insert labeling. The updated label itself isn't posted on the FDA's site yet.
Nothing in the filing signals a broader win. There's no new indication, no shift in safety or efficacy language described, which makes this a routine refresh of prescribing paperwork for an approved product. The capsule strengths listed on the application remain 20 mg and 80 mg (base).
Investors watching EXEL have seen this kind of headline before. Across 29 sessions following earlier Exelixis announcements, the stock closed higher 19 times and lower 10 times, with a median move of 2.1% in either direction. Those figures track timing only, and many forces move a stock in a single session.
Recent reaction points were all over the map. Shares rose 4.8% the session after Exelixis posted third-quarter 2026 results on Oct. 30, 2026, while they slipped 1.0% after the company said it would release those results on Oct. 29. On Aug. 19, 2026, a new price target from BMO Capital Markets as it initiated coverage preceded a 2.4% gain. Exelixis has traded publicly since 2000 and sits in the Health Care sector.
TopicsExelixis · COMETRIQ · cabozantinib · FDA · EXEL · NDA 203756 · BMO Capital Markets
Source: quantisnow.com
Written by AI from verified reporting.
More stories
- Health & science abc.net.au Caught by @nandahidayat 3 viewsRallies across Australia hit back at insurance rule change threatening homebirths
- Health & science nbcnews.com Caught by @doni.putri23 1 viewFederal panel favors HPV tests over Pap smears, adds self-collection option
- Health & science medicalxpress.com Caught by @ajayy30 1 viewGuinea Pig Ears Upend the Nobel-Winning Map of How We Hear
- Health & science phys.org Caught by @ajayy30 0 viewsLopsided galaxies are shaped from within, catalog of 606 suggests

